Situation Far From Ideal But EU Network Will Survive Brexit
Executive Summary
Brexit undoubtedly will cause some short-term disruption to the EU medicines regulatory network but the network will survive without the UK. That’s according to former European Medicines Agency head Thomas Lönngren. Meanwhile, the timetable for relocating the EMA is likely to be finalized in a few days’ time – as are the criteria for hosting the agency when it moves from London.
You may also be interested in...
Massive Reallocation of UK Rapporteurships Likely As EMA Plans For Future; UK’s Interim Role Uncertain
If Brexit means the UK no longer plays a part in the EU drug regulatory system, responsibility for the ongoing oversight of almost one in four of all the human medicines that have ever been approved under the centralized procedure will have to be reassigned from the UK to other member states. What Brexit means for the UK’s role as a key player in the regulatory system in the meantime is the subject of speculation.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.